Results from a first-in-human study (PROCLAIM-CX-2029) in patients (Pts) with advanced cancer - In Conclusion - Melissa Lynne Johnson MD - Sarah Cannon Research Institute @SarahCannonPR #...

Results from a first-in-human study (PROCLAIM-CX-2029) in patients (Pts) with advanced cancer - In Conclusion - Melissa Lynne Johnson MD - Sarah Cannon Research Institute @SarahCannonPR #...

User Photo
Cancer-News

1 week
4 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:

Melissa Johnson, MD, Associate Director, Lung Cancer Research and Drug Development, Sarah Cannon Research Institute at Tennessee Oncology discusses CX-2029, a PROBODY drug conjugate targeting CD71 (transferrin receptor): Results from a first-in-human study (PROCLAIM-CX-2029) in patients (Pts) with advanced cancer. 

ASCO

https://meetinglibrary.asco.org/record/185085/abstract

Up Next Autoplay